1741. A Phase 4, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, and Immunogenicity of Vaxelis™ in Healthy Children Previously Vaccinated With a 2-Dose Primary Infant Series of Either Vaxelis™ or Hexyon™ (V419-016)

BACKGROUND: Vaxelis™ is a hexavalent combination vaccine (HCV) indicated in infants and toddlers for the prevention of diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and invasive disease due to Haemophilus influenzae type b. In practice, switching between HCVs during the childhood vacci...

Descripción completa

Detalles Bibliográficos
Autores principales: Guerra, Andrea, Costantino, Claudio, Martinon-Torres, Federico, Westerholt, Soeren, Lambeth, Courtney, Chen, Ziqiang, Lumley, Jessie, Johnson, David, Wilck, Marissa B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677302/
http://dx.doi.org/10.1093/ofid/ofad500.1572

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677302/
http://dx.doi.org/10.1093/ofid/ofad500.1572

Ejemplares similares